Kornimate/medical-research-clean huggingface dataset:
investigation of the effects of exercise and kinesiological taping on spinal deformities and serum markers in individuals with scoliosis

Conditions: Scoliosis; Scoliosis Idiopathic; Musculoskeletal Deformity

Summary: the aim of this study is to investigate the effects of schroth exercises and kinesiological taping on spinal deformities and serum markers in young adults with scoliosis. the study will include young adults aged 18-21 with scoliosis. a total of 57 participants will be included in the study. out of 57 participants, 38 have scoliosis, and 19 are healthy. 38 participants will be randomly divided into 2 groups. one group (n=19) will receive only schroth exercises, and the other group (n=19) will receive both schroth exercises and kinesiological taping. the laboratory analyses of proteins associated with autophagy (beclin-1, lc3, and atg3) and bone-cartilage metabolism (comp and mmp-3) will be conducted in the biomedical engineering laboratory of our university. trunk rotation will be assessed using the adams forward bend test with scoliometer, quality of life will be evaluated with the srs-22 quality of life questionnaire and quality of life profile for spinal deformities questionnaire, perception of deformity will be measured using the walter reed visual assessment scale, and cobb angles will be evaluated from anterior-posterior x-ray images.

the aim of this study is to investigate the effects of schroth exercises and kinesiological taping on spinal deformities and serum markers in young adults with scoliosis. the study will include young adults aged 18-21 with scoliosis. a total of 57 participants will be included in the study. out of 57 participants, 38 have scoliosis, and 19 are healthy. 38 participants will be randomly divided into 2 groups. one group (n=19) will receive only schroth exercises, and the other group (n=19) will receive both schroth exercises and kinesiological taping. the laboratory analyses of proteins associated with autophagy (beclin-1, lc3, and atg3) and bone-cartilage metabolism (comp and mmp-3) will be conducted in the biomedical engineering laboratory of our university. schroth exercises will be administered to both groups twice a week for 12 weeks. kinesiological taping will be applied twice a week to the group receiving both schroth exercises and kinesiological taping. pre-treatment evaluations will include assessments of cobb angles, trunk rotation, serum markers, quality of life and perception of deformity. post treatment evaluations will include assessments of trunk rotation, cobb angles, serum markers, quality of life and perception of deformity.

Eligibility criteria:
inclusion criteria: * the individuals who agree to the study conditions and will continue with the treatment protocol. * 18-21 years * individuals with scoliosis exclusion criteria: * individuals with metabolic problems such as diabetes, thyroid issues, kidney problems, etc. * individuals with joint diseases such as septic arthritis, viral arthritis, rheumatoid arthritis, etc.

Keywords: scoliosis exercise
secondary prognostic index in refractory lymphoma

Conditions: Diffuse Large B Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma

Summary: 60% of patients with diffuse large b cell lymphoma are healed after first-line treatment which whatever the age. for the remaining 40% of patients (relapses and primary refractories): * 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years. * for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%. * the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life. palliative care is rarely offered as part of the treatment overall load.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * died of diffuse large b cell lymphoma * refractory or relapsing after 2 treatment lines for young patients (rchop then recovery with platinum salts and autograft) and one line for elderly patients (rchop) exclusion criteria: * patients with hiv infection * solid tumor treated less than 5 years ago with the exception of skin carcinoma or carcinoma in situ of the uterine cervix treated locally * inclusion in a therapeutic trial

Keywords: prognostic score cancer
the predictive role of c-reactive protein to albumin ratio (car) in the treatment of septic arthritis in young chlidren

Conditions: Septic Arthritis

Summary: purpose: c-reactive protein to albumin ratio (car) has emerged as a novel marker of inflammation. however, almost no research has evaluated the role of car in septic arthritis (sa). there is currently controversy over the timing of surgery. our aim is to explore the application of the car in predicting the treatment choice for sa in children under 4 years of age. methods: retrospective analysis of the clinical data from children under four years of age admitted to the department of orthopedics at children's hospital of soochow university between january 2016 and december 2022 due to sa. patients were divided into surgery group and conservative group based on whether the patients underwent surgery. the clinical data of the two groups were compared. multivariate logistic regression analysis was performed to determine the independent predictors for sa requiring surgical intervention. receiver operating characteristic (roc) curves were plotted for the independent predictive indicators, and the area under curve (auc) was determined. the cut-off value was determined using youden index, and diagnostic accuracy indicators such as sensitivity (sen), specificity (spe), positive predictive value (ppv) and negative predictive value (npv) were calculated.


Eligibility criteria:
inclusion criteria: * (1) meeting the aforementioned sa diagnostic criteria, regardless of the affected joint; (2) completing routine blood and biochemical tests within 24 hours of admission; (3) no surgery or antibiotics administered prior to admission. exclusion criteria: * (1) cases of transient synovitis, rheumatism-related diseases (jia, etc.), simple acute hematogenous osteomyelitis, or acute exacerbation of chronic hematogenous osteomyelitis after revision of the diagnosis; (2) postoperative iatrogenic infection; (3) incomplete clinical data.
hepasphere chemoembolization in advanced hcc patients: safety & efficacy registry in china

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this multicenter registry is to gather the safety, efficacy and survival data in advanced hcc patients treated with hepasphere in china in order to evaluate the application of hepasphere detace in treating advanced hcc patients


Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. patient has signed informed consent 3. patient must have a diagnosis of hepatocellular cancer by at least one of the following method: 1. histological confirmation 2. classic imaging characteristics of hcc: early enhancement (arterial hypervascularity) and venous or delayed phase washout in multidetector contrast enhanced computed tomography (ct) scan / dynamic contrast-enhanced magnetic resonance imaging (mri) imaging. * either ct/ mri shows at least one solid liver lesion ≥ 2 cm with the above described imaging characteristics of hcc. * in case of liver lesion between 1 and 2 cm, both ct and mri imaging have to be performed in order to confirm the imaging characteristics of hcc. 4. at time of study entry. 1. patients not suitable for ablation due to lesion location may be enrolled 2. patients with hcc recurrence but not suitable for resection or ablation maybe enrolled 5. patient must be with bclc stage c and meet the following criteria: * stage child-pugh a or b and * performance status ecog ≤ 2 with vascular invasion or without vascular invasion 6. patient has a life expectancy of at least 6 months exclusion criteria: 1. current or previous treatment with chemo- or radiation therapy or sorafenib 2. previous treatment of transarterial chemoembolization (tace) 3. patients with current or history of any other cancer except non-melanomatous skin cancer 4. female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive 5. performance status ecog \> 2 6. child-pugh class c 7. occlusive tumor thrombus to the main portal trunk 8. active gastrointestinal bleeding 9. evidence of uncorrectable bleeding diathesis 10. extra-hepatic spread of the hcc 11. \>50% tumor involvement of the liver 12. infiltrative hcc 13. encephalopathy not adequately controlled medically 14. presence of ascites not controlled medically 15. any contraindication for mri/ ct (eg. metallic implants) 16. allergy to contrast media that cannot be managed with prophylaxis 17. any contraindication to arteriography 18. any contraindication for doxorubicin administration

Keywords: hepasphere
embolectomy in acute sylvian thrombosis in refractory or ineligible patients to alteplase

Conditions: Stroke, Acute

Summary: this trial aims at comparing two strategies currently used to address acute ischemic stroke of the middle cerebral artery : medical treatment without endovascular treatment on the one hand, and medical treatment plus endovascular treatment on the other hand. the efficiency of the strategies will be assessed in terms of early neurological clinical recovery. the study will focus on three particular situations : (1) tandem internal carotid and middle cerebral artery occlusion, (2) situations where patient cannot benefit from fibrinolysis because of high risk of haemorrhage, (3) situations where fibrinolysis is not recommended because of a delay superior to 4.5 hours. the hypothesis to be tested is that medical approach plus endovascular treatment is superior to medical treatment alone


Eligibility criteria:
inclusion criteria: * radiologically proven acute proximal occlusion of middle cerebral artery and one of the three following : 1. tandem internal carotid / middle cerebral artery occlusion 2. intravenous thrombolysis contraindicated because of high risk of haemorrhage 3. intravenous thrombolysis not possible because of delay \> 4.5 hours exclusion criteria: * impossibility to perform endovascular recanalization within 6h * clinically minor stroke (nihss score below 5 at baseline) * extended cerebral infarction * severe comorbidity * life expectancy below 3 months before stroke * pregnancy or breastfeeding * modified rankin score superior to 2 before stroke

Keywords: stroke endovascular treatment tandem carotid occlusions fibrinolysis
the fifth-year follow-up study for the phase iv clinical trial of hepatitis a vaccine in healthy children

Conditions: Hepatitis A

Summary: the purpose of this follow-up study is to evaluate the five-year immune persistence of one injection of inactivated and attenuated alive hepatitis a vaccine in healthy children.

in the previous double-blind, randomized, phase iv clinical trial in 2008, 300 healthy chinese children aged 18 to 35 months old were administered with one dose of inactivated and attenuated alive hepatitis a vaccine. series of serum samples were taken for immunogenicity and immune persistence evaluation. safety observations were performed after vaccination. this trial was also approved by tianjin cdc biomedical ethics committee in 2008. this study is the fifth-year follow-up research for the previous clinical trial.

Eligibility criteria:
inclusion criteria: * all subjects who received inactivated or attenuated alive hav vaccine in the previous trial exclusion criteria: * subjects who refused to continue in the follow-up study

Keywords: hepatitis a inactivated hepatitis a vaccine attenuated alive hepatitis a vaccine immune persistence
comparison of nutritional products for people with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: part a: to compare the glucose and insulin responses of a standard tube feeding product to that of a diabetes-specific tube feeding product in individuals with type 2 diabetes. part b: to compare the glucose response of a standard tube feeding product to that of a diabetes-specific tube feeding product when consumed by individuals with type 2 diabetes as a sole source of nutrition.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent form * type 2 diabetes * 18 to 75 years of age * male or non-pregnant, non-lactating female, at least 6 weeks postpartum * if female is of childbearing potential, is practicing birth control * bmi greater than or equal to 18.5 kg/m2 and less than 40.0 kg/m2 * medications, such as antihyperglycemic or thyroid medications or hormone therapy, have been maintained at a constant dosage for at least two months prior to screening visit exclusion criteria: * uses exogenous insulin for glucose control * type 1 diabetes * history of diabetic ketoacidosis * current infection; has received corticosteroid treatment in the last 3 months, or has had surgery or received antibiotics in the last 3 weeks * active malignancy * significant cardiovascular event less than 12 weeks prior to study entry * end stage organ failure or is status post organ transplant * has an active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion excluding diabetes * chronic, contagious, infectious disease, such as active tuberculosis, hepatitis b or c, or hiv * taking any herbals, dietary supplements or medications, other than antihyperglycemic medications during the past four weeks that could profoundly affect blood glucose * fainted or experienced other adverse reactions in response to blood collection prior to this study * has clotting or bleeding disorders * allergic or intolerant to any ingredient found in the study products * participant in a concomitant trial that conflicts with this study
emepic : value of a mobile team of cardiologist using echocardiography for managing patients with acute heart failure

Conditions: Acute Heart Failure; Congestive Edema; Cardiac Disease

Summary: the aim of the study is to compare clinical management of patients with acute decompensation of heart failure, hospitalized in non cardiological ward, with the use of a mobile team including a cardiologist with portable echocardiography and standard care. the hypothesis is that a mobile team will lead to shorter hospitalization.

randomized, controlled, monocentric study comparing standard care with the care provided by a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward on the duration of hospitalization, re-hospitalization rate à 30 days, emergency visit within 30 days, treatment at discharge, mortality within hospital stay and at 30 days.

Eligibility criteria:
inclusion criteria: * hospitalized for suspected heart failure * \> or = 18 years exclusion criteria: * refuses to participate

Keywords: heart failure, congestive echocardiography patient care team
comparison of insulin detemir with nph insulin in type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in africa, asia, europe, oceania, and south america. the aim of this research study is to compare the efficacy (reduction in hba1c and in blood glucose levels) of insulin detemir compared to nph insulin administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight, and insulin antibodies and side effects).


Eligibility criteria:
inclusion criteria: * type 1 diabetes * currently on basal-bolus regimen * bmi = 35.0 kg/m2 * hba1c =11.0% exclusion criteria: * proliferative retinopathy or maculopathy * recurrent major hypoglycaemia * cardial problems * uncontrolled hypertension * impaired hepatic or renal function
evaluation of different scaffolds in regenerative endodontic treatment

Conditions: Endodontic Disease; Regenerative Endodontics

Summary: the aim of this study is to evaluate and compare the regenerative potentials of injectable platelet-rich fibrin (i-prf), platelet-rich fibrin (prf), and blood clot (bc) as different scaffolds regarding: radiographic outcomes (increase of root length, increase in thickness of dentinal wall, healing of periapical lesion, and apical closure). clinical outcomes in the treatment of young, immature permanent teeth with necrotic pulps.


Eligibility criteria:
inclusion criteria: * necrotic immature permanent anterior teeth. * teeth not indicated for post/core final restoration. * radiographically: the root has incomplete development with an apical opening of more than 1 mm. exclusion criteria: * medically compromised patients with blood and immunity disorders. family history of autoimmune disorder. also, patients with physical or mental handicapping conditions. * teeth with questionable restorability of the remaining crown/root structure. * pathological tooth mobility. * radiographically: evidence of root fracture or root resorption (external or internal).

Keywords: prf regeneration blood clot scaffolds
reliability of rimegepant or triptans for the acute treatment of migraine

Conditions: Migraine Disorders

Summary: this protocol describes the analysis of the adelphi real world (arw) migraine disease specific programme(tm) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.

this is a retrospective database study that aims to explore the reliability of effect with acute use of rimegepant or triptans, to evaluate the satisfaction with rimegepant or triptans, to evaluate willingness to continue using rimegepant or triptans, and to explore proportion optimized on treatment with rimegepant or triptans. the data will be extracted from the adelphi real world (arw) migraine disease specific programmetm (dsp) 2022 database, which was conducted across a number of countries including united states, between may 2022 and november 2022. the dsp was an observational study of clinical practice. treatment practice data were collected by physicians (physician survey) who were asked to provide information for the next 10 patients consulting for migraine. these patients were then invited to fill out a self-completion form (patient survey) providing their own assessment on the disease and treatments.

Eligibility criteria:
inclusion criteria * patients who have episodic and/or chronic migraine * patients age \> 18 * currently prescribed rimegepant or triptans for the acute treatment of migraine exclusion criteria * currently prescribed rimegepant for prevention of migraine or for both the acute treatment \& prevention of migraine * rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant * triptan group: currently prescribed an acute treatment for migraine other than triptans
the impact of adequate water intake on exercise performance and mood in women and men

Conditions: Dehydration; Mood

Summary: dehydration is defined as the state of water deficit due to excessive water losses and/or small water intake. underhydration is the result of inadequate water intake leading to activation of water hormonal homeostasis, characterized by elevated vasopressin, lower urinary output, and concentrated urine without any measurable changes in total body water. it is well established that dehydration (water deficit) decreases exercise performance and worsens mood, mainly in women. however, the impact of increased water intake in underhydrated individuals on their exercise capacity and mood is not known. the aim of the proposed study is to investigate the impact of increased water intake in underhydrated individuals on aerobic exercise performance and mood in both women and men.


Eligibility criteria:
inclusion criteria: * healthy adults * residence in arizona exclusion criteria: * use of diuretics * use of anti-depressive medication * current pregnancy or lactation * current use of injectable insulin * diagnosed with irritable bowel syndrome * do not pass the physical activity readiness questionnaire for everyone (par-q) screening
safety and pharmacokinetics of tt30 in subjects with paroxysmal nocturnal hemoglobinuria (pnh)

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the purpose of this research study is to understand the safety, pharmacokinetics and pharmacodynamics of a single dose of tt30 (alxn1102 and alxn1103 formulations) when given iv (through a vein) or sc (under the skin) to patients with pnh.

this is an open-label, single-dose, dose-escalation study to assess the safety, tolerability, pk, pd, and immunogenicity of tt30 given as an iv infusion and as a sc injection in subjects with pnh or evidence of circulating pnh cells. eligible subjects with pnh will be vaccinated with meningococcal vaccine at least two weeks prior to dosing (if not previously vaccinated or if revaccination is required). on study day 1, the subject will receive the single dose of tt30 as an iv infusion over 60 minutes or as a sc injection, and be followed with additional study evaluations over the next 59 days.

Eligibility criteria:
inclusion criteria: * individuals at least 18 years of age with a diagnosis of pnh \& vaccination against meningococcus. exclusion criteria: * abnormal renal or liver function * history of meningococcal disease * history of guillain-barre syndrome * known infection with hiv or hepatitis b or c * history of thrombotic events

Keywords: pnh
efficacy and safety of desmopressin (nocturin®) 0.1 mg tablets in treatment of nocturia in participants with benign prostate syndrome (bps)

Conditions: Nocturia Associated With Nocturnal Polyuria

Summary: documentation of the efficacy and safety of desmopressin (nocturin®) 0.1 mg tablet. observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.


Eligibility criteria:
inclusion criteria: * therapeutic need according to summary of product characteristics * written informed consent exclusion criteria: * contraindications according to summary of product characteristics